| Attribute |
Value |
| 52 Week Change |
-0.57395077 |
| Address1 |
315 Montgomery Street |
| Address2 |
10th Floor |
| All Time High |
35,700.0 |
| All Time Low |
4.91 |
| Ask |
9.39 |
| Ask Size |
1 |
| Average Daily Volume10 Day |
38,860 |
| Average Daily Volume3 Month |
54,777 |
| Average Volume |
54,777 |
| Average Volume10Days |
38,860 |
| Beta |
0.855 |
| Bid |
0.3008 |
| Bid Size |
1 |
| Book Value |
1.997 |
| City |
San Francisco |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
7.36 |
| Current Ratio |
2.608 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
7.4 |
| Day Low |
6.5 |
| Display Name |
GT Biopharma |
| Dividend Date |
1,503,273,600 |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,755,518,400 |
| Earnings Timestamp Start |
1,754,996,340 |
| Ebitda Margins |
0.0 |
| Enterprise Value |
8,321,237 |
| Eps Forward |
-10.8 |
| Eps Trailing Twelve Months |
-147.5 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
7.1078 |
| Fifty Day Average Change |
0.25220013 |
| Fifty Day Average Change Percent |
0.035482164 |
| Fifty Two Week Change Percent |
-57.395077 |
| Fifty Two Week High |
28.75 |
| Fifty Two Week High Change |
-21.39 |
| Fifty Two Week High Change Percent |
-0.74399996 |
| Fifty Two Week Low |
4.91 |
| Fifty Two Week Low Change |
2.4500003 |
| Fifty Two Week Low Change Percent |
0.49898174 |
| Fifty Two Week Range |
4.91 - 28.75 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,522,157,400,000 |
| Float Shares |
1,701,909 |
| Forward Eps |
-10.8 |
| Forward P E |
-0.6814815 |
| Free Cashflow |
-8,872,375 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
1 |
| Fullday Change |
0.19000006 |
| Fullday Change Percent |
2.5815225 |
| Fullday Price |
7.55 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.10349 |
| Held Percent Institutions |
0.085260004 |
| Implied Shares Outstanding |
2,061,052 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-02-11 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,788,825,600 |
| Last Split Factor |
1:25 |
| Long Business Summary |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. |
| Long Name |
GT Biopharma, Inc. |
| Market |
us_market |
| Market Cap |
15,169,343 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_265434 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-11,380,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
12,811,090 |
| Number Of Analyst Opinions |
1 |
| Open |
6.5 |
| Operating Cashflow |
-14,426,000 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Peg Ratio |
1.05 |
| Phone |
415 919 4040 |
| Pre Market Change |
0.19000006 |
| Pre Market Change Percent |
2.5815225 |
| Pre Market Price |
7.55 |
| Pre Market Time |
1,792,151,447 |
| Previous Close |
6.21 |
| Price Hint |
2 |
| Price To Book |
3.6855285 |
| Profit Margins |
0.0 |
| Quick Ratio |
2.235 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
1.15 |
| Regular Market Change Percent |
18.5185 |
| Regular Market Day High |
7.4 |
| Regular Market Day Low |
6.5 |
| Regular Market Day Range |
6.5 - 7.4 |
| Regular Market Open |
6.5 |
| Regular Market Previous Close |
6.21 |
| Regular Market Price |
7.36 |
| Regular Market Time |
1,792,094,401 |
| Regular Market Volume |
62,956 |
| Return On Assets |
-1.58157 |
| Return On Equity |
-1.1352301 |
| Sand P52 Week Change |
0.16207206 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
2,061,052 |
| Shares Percent Shares Out |
0.1438 |
| Shares Short |
259,425 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
153,686 |
| Short Name |
GT Biopharma, Inc. |
| Short Percent Of Float |
0.1439 |
| Short Ratio |
2.24 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
GTBP |
| Target High Price |
75.0 |
| Target Low Price |
75.0 |
| Target Mean Price |
75.0 |
| Target Median Price |
75.0 |
| Total Cash |
4,960,000 |
| Total Cash Per Share |
2.749 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-147.5 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
10.4452 |
| Two Hundred Day Average Change |
-3.0851998 |
| Two Hundred Day Average Change Percent |
-0.2953701 |
| Type Disp |
Equity |
| Volume |
62,956 |
| Website |
https://www.gtbiopharma.com |
| Zip |
94,104 |